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derive optimized α and α /β of 0.3Gy-1 and 6Gy, respectively. 
We also found a generalized mean value of a=-1.7 (95% 
confidence interval upper bound=-0.1), which produces the 
best performing gTD predictive metric (Fig.). 
Conclusions: A negative 'a' value suggest that areas of low 
cell survival (high dose) play a driving role in determining 
whether local control is achieved, regardless of dose 
homogeneity. In this first known case of multi-institutional 
investigation of case-specific treatment effects, we 
demonstrated the utility and superior predictive power of 
this novel, biologically-inspired dose-metric. 
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Purpose/Objective: Medically inoperable early stage non-
small cell lung cancer (NSCLC) is frequently treated with 
stereotactic body radiotherapy (SBRT). As this patient 
population is often frail, not only is surgery a potential 
morbid procedure, but obtaining a pathologic diagnosis of 
cancer may be risky as well. It is becoming more common to 
treat patients empirically with growing, positron emission 
tomography (PET) avid lung nodules with SBRT. This study 
looked to compare outcomes between patients with a 
histopathologic diagnosis of cancer compared to patients 
without a diagnosis. 
Materials and Methods: A retrospective review of patients 
enrolled on a prospective IRB-approved registry from 2004 to 
2013 was conducted. Patients with a non-diagnostic biopsy or 
no attempted biopsy were considered to lack a 
histopathologic diagnosis. Patients with synchronous cancers 
or prior invasive malignancy within 2 years of SBRT were 
excluded. Kaplan-Meier curves for local control (LC), 
progression-free survival (PFS), recurrence-free survival 
(RFS), and overall survival (OS) were created by Wilcoxon 
analysis. Patients were evaluated for risk factors predicting 
for LC, PFS, RFS, and OS using Cox regression. 
Results: A total of 427 patients were included in the analysis. 
Median age was 74 years old with a median follow-up of 17 
months (range, 0.2 to 105 months). Of all patients, 332 (78%) 
underwent biopsy confirming diagnosis of malignancy, with 
124 (37%) patients with adenocarcinoma, 98 (30%) patients 
with squamous cell, 98 (30%) patients with NSCLC not 
otherwise specified, and 12 (4%) patients with other 
histologies. Ninety-five patients (22%) were treated 
empirically for suspected lung cancer, of which 92 (97%) were 
staged with PET/CT. Patients treated without a diagnosis 
were more likely to have a prior history of cancer, smaller 
tumors, lower BMI, and a lower PET standardized uptake 
value maximum compared with patients with a diagnosis. 
There was no difference between the groups at baseline with 
regard to age, race, gender, smoking status, Charlson 
comorbidity score, KPS, central location, use of mediastinal 
staging, or use of PET/CT staging. For the entire cohort, 2 
year LC, PFS, RFS and OS was 91%, 47%, 64% and 61%, 
respectively. There was no difference in LC, PFS, RFS, and OS 
between patients with and without biopsy. On multivariate 
analysis, factors predictive for improved OS included KPS ≥70 
{hazard ratio (HR) 0.552 [95% confidence interval (CI), 0.383-
0.796, p=0.005]}, larger CT size of tumor [HR 1.195 (95% CI, 
1.033-1.383), p=0.003] and post-treatment CT scan showing 
partial or complete response [HR 0.399 (95% CI, 0.164-0.968, 
p=0.012)]. 
Conclusions: In carefully selected patients without a biopsy, 
SBRT results in comparable survival and tumor control 
compared with patients treated with a biopsy. 
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Purpose/Objective: To identify prognostic factors for brain 
relapses. A secondary analysis of a prospective randomized 
trial of definitive radiochemotherapy (RT/CT) compared with 
neoadjuvant RT/CT+surgery was performed. 
Materials and Methods: Pts with pathologically proven 
operable IIIA(N2) / selected IIIB NSCLC received 3 cycles 
cisplatin/paclitaxel and neoadjuvant chemoradiotherapy to 
45 Gy (1.5 Gy bid/ concurrent cisplatin/ vinorelbine). Pts 
were reevaluated within an interdisciplinary panel during last 
week of RT/CT. Operable pts were randomized either to 
definitive RT/CT (arm A: risk- adapted boost to 65/71 Gy at 2 
Gy per fraction without break and concurrent 
cisplatin/vinorelbine) or surgery (arm B). Depending on 
institutional policy, PCI could be applied after completion of 
chemotherapy. 
Results: Between 1/2004 and 8/2012, 246 pts (70 F/176 M; 
stages, 75 T1-3 N2 / 80 T4 N0-1/ 91 T4 N2 or T1-3N3; 
histology, 95 SCC / 107 ADC / 44 other) were enrolled from 5 
centers, 161 patients were randomised (arm A: 80 pts, arm 
B:81 pts). Brain relapse as part of any relapse was observed 
in 33 randomised pts, isolated brain failures were detected in 
23 pts. Freedom from isolated brain relapse (FFIBR) at 2 
years was 84 (78-90)% for all patients, arm A 83 (73-93)%, 
arm B 81 (71-91)%. 42 pts recieved prophylactic cranial 
irradiation. PCI did not influence the incidence of isolated 
brain relapses (FFIBR at 2 years with or without PCI: 84 (70-
98)% vs 81 (73-89)%, p=0.93). Factors associated with a higher 
incidence of isolated brain relapses in univariate analysis 
were female gender (FFIBR at 2 years: 89 (81-97)% (male) vs 
72 (58-86)%, p=0.03) and TN-stage subgroup (FFIBR at 2 
